Ofev (nintedanib) Disease area(s): Respiratory Manufacturer(s): Boehringer Ingelheim 2024 Sales (USD): $4.07 billion Why it sold so well: In 2024, Boehringer Ingelheims Ofev achieved significant commercial success, with global sales reaching 3.77 billion ($4.07 billion), marking a 7.3% increase at constant exchange rates compared to the previous year
Those with diabetic retinopathy should be monitored for worsening of this condition
Key areas affected include: Cheeks and mid-face region Temples and forehead Under-eye areas Jawline and chin The body typically loses facial fat uniformly, but individual genetics influence which areas experience the most dramatic changes
Scientific References Frequently Asked Questions Can I have B12 injections more frequently if symptoms return early
Consumers using GLP-1 medications are seeking more products with protein, fiber and healthy fats while reducing purchases of products high in carbohydrates and sugar, creating potential implications across grocery aisles, pharmacies, product portfolios, merchandising strategies and shopper engagement